Source: Annual Congress 2010 - Pre-clinical models of airways disease
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Shenoy, A. Ferreira, Y. Qi, R. Fraga-Silva, A. Dooies, S. Sriramula, J. Francis, T. Reudelhuber, R. Santos, M. Raizada, M. Katovich (Gainesville, Baton Rouge, United States Of America; Belo Horizonte, Brazil; Montreal, Canada). LSC 2010 Abstract: Overexpression of Ang-(1-7)-fusion protein in the lungs prevents pulmonary fibrosis and accompanying pulmonary hypertension. Eur Respir J 2010; 36: Suppl. 54, 5147

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - NGF induces pulmonary arterial hyperreactivity through increased connexin-43 expression: potential role in pulmonary hypertension Source: International Congress 2018 – Molecular mechanisms and treatment of pulmonary hypertension Year: 2018 Role of tadalafil in patients with hypoxia / lung disease induced (group 3) pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Role of dendritic cells in pulmonary fibrosis in mice Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Sildenafil decreases the contractile response to serotonin (5HT) in pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2015 – IPF pathogenesis Year: 2015 Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity Source: Eur Respir J 2005; 26: 586-593 Year: 2005 Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 39: 359-365 Year: 2012 LSC Abstract – Enhanced expression of alarmins in pulmonary hypertension and fibrosis Source: International Congress 2016 – Repair pathways: from lung development to ageing of the lung Year: 2016 Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Plasma protein signature of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 Sildenafil inhibit dose-dependently profibrotic and remodelling effects of TGFbeta1 on pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 The immunomodulatory effect of protein S in pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Time-course changes in pulmonary haemodynamics in patients with idiopathic pulmonary fibrosis (IPF) waiting for lung transplantation (LT) Source: Eur Respir J 2004; 24: Suppl. 48, 668s Year: 2004 Abnormal pulmonary arterial remodelling in patients with combined pulmonary fibrosis emphysema (CPFE) and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2011 - Clinical approach of diffuse parenchymal lung disease Year: 2011 17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice Source: International Congress 2016 – ILD pathogenesis Year: 2016 LATE-BREAKING ABSTRACT: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis Year: 2014 Nintedanib has acute pulmonary vasodilatory effects in transgenic Fra2 mice with spontaneous progressive pulmonary hypertension and lung fibrosis. Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019